EFM-19 Xenograft Model Service for Breast Cancer

The EFM-19 xenograft model stands as a sophisticated in vivo platform specifically engineered for evaluating endocrine therapies and investigating the complexities of Luminal B breast cancer. Alfa Cytology provides an industry-leading EFM-19 xenograft model service, combining our deep oncology expertise with optimized protocols to deliver high-fidelity data that accelerates your drug discovery milestones.

Overview of EFM-19 Xenograft Model for Breast Cancer

The EFM-19 cell line is a human breast cancer model derived from the metastatic pleural effusion of a patient with ductal carcinoma. It is a quintessential representative of the Luminal B molecular subtype, characterized by the expression of estrogen receptor (ER) and progesterone receptor (PR). Unlike many other models, EFM-19 is known for its strong dependency on estrogen for growth, making it a gold-standard in vivo platform for studying hormone-receptor-positive breast cancer and endocrine resistance.

One of the defining genetic features of the EFM-19 model is the presence of the PIK3CA (His1047Leu) mutation, a common driver in human breast cancer that impacts the PI3K/AKT/mTOR signaling pathway. This model is extensively used to screen novel selective estrogen receptor modulators (SERMs), degraders (SERDs), and combination therapies involving CDK4/6 inhibitors.

Cell Line Information: EFM-19

The EFM-19 cell line maintains high receptor fidelity and typically exhibits an epithelial morphology in vitro.

Alfa Cytology is committed to delivering scientifically rigorous results for your most challenging oncology projects. Our technical team specializes in the precise execution of hormone-dependent models, utilizing specialized in vivo supplement strategies to ensure the EFM-19 model faithfully recapitulates human disease.

Our Services

Workflow of EFM-19 Xenograft Model Construction

Alfa Cytology follows a standardized, ethically compliant workflow to establish the EFM-19 xenograft model:

• Cell Expansion: EFM-19 cells are cultured under optimized conditions. We perform routine quality control, including receptor expression verification and mycoplasma testing, before in vivo inoculation.
• Host Selection & Preparation: Healthy immunocompromised mice are selected. Due to the high estrogen dependency of EFM-19, animals receive a specialized estrogen supplementation protocol (e.g., 17β-estradiol pellet implantation) to support stable tumor growth.
• Precise Inoculation: A high-viability suspension of EFM-19 cells is prepared and combined with a biological matrix carrier. The cells are precisely injected in vivo, typically via the mammary fat pad (orthotopic) or subcutaneous routes.
• Longitudinal Monitoring: We conduct regular, systematic monitoring of tumor volume and animal health. Our team utilizes precision calipers to track growth kinetics, ensuring the data captured is accurate and publication-ready.
• Randomization: Once tumors reach a consistent and statistically relevant growth threshold, mice are randomized into treatment cohorts. This step minimizes initial bias and ensures the statistical power of the efficacy study.

Fig 1. EFM-19 Xenograft Model Construction Workflow

Case Study - EFM-19 Xenograft Model Development

In a recent validation study at Alfa Cytology, the EFM-19 xenograft model was utilized to evaluate a novel combination of a SERD candidate and a CDK4/6 inhibitor. The model demonstrated exceptional sensitivity to the synergistic therapy, showing a clear growth inhibition compared to monotherapy groups.

Why Choose Alfa Cytology?

• Luminal Subtype Expertise: Proven success in establishing and maintaining slow-growing, hormone-dependent models.
• Hormone Support Optimization: Advanced techniques for estrogen supplementation to ensure consistent tumor take.
• Genomic Integration: Deep understanding of the PIK3CA mutation status for targeted therapy research.
• Customizable Endpoints: Comprehensive options for biomarker analysis, PK/PD correlation, and high-resolution histology.

Contact Us

Elevate your endocrine therapy research with the specialized EFM-19 xenograft platform. Our scientists at Alfa Cytology are ready to provide the technical depth and experimental precision your project deserves. Please reach out to us today to design your custom study, or contact us directly to request a project-specific quote.

For research use only. Not intended for any clinical use.